A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 07 Feb 2018 Planned primary completion date changed from 11 Feb 2018 to 14 Nov 2018.
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2017 Planned End Date changed from 15 Jun 2018 to 14 Nov 2018.